Naughton Sean X, Raval Urdhva, Pasinetti Giulio M
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA.
James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA.
J Pers Med. 2020 Jul 29;10(3):74. doi: 10.3390/jpm10030074.
Early diagnosis of Alzheimer's disease (AD) and the identification of significant risk factors are necessary to better understand disease progression, and to develop intervention-based therapies prior to significant neurodegeneration. There is thus a critical need to establish biomarkers which can predict the risk of developing AD before the onset of cognitive decline. A number of studies have indicated that exposure to various microbial pathogens can accelerate AD pathology. Additionally, several studies have indicated that amyloid-β possess antimicrobial properties and may act in response to infection as a part of the innate immune system. These findings have led some to speculate that certain types of infections may play a significant role in AD pathogenesis. In this review, we will provide an overview of studies which suggest pathogen involvement in AD. Additionally, we will discuss a number of pathogen-associated biomarkers which may be effective in establishing AD risk. Infections that increase the risk of AD represent a modifiable risk factor which can be treated with therapeutic intervention. Pathogen-based biomarkers may thus be a valuable tool for evaluating and decreasing AD risk across the population.
早期诊断阿尔茨海默病(AD)并识别重要风险因素,对于更好地理解疾病进展以及在显著神经退行性变之前开发基于干预的疗法至关重要。因此,迫切需要建立能够在认知能力下降之前预测患AD风险的生物标志物。多项研究表明,接触各种微生物病原体可加速AD病理进程。此外,多项研究表明,淀粉样β蛋白具有抗菌特性,可能作为先天免疫系统的一部分对感染作出反应。这些发现促使一些人推测,某些类型的感染可能在AD发病机制中起重要作用。在本综述中,我们将概述提示病原体参与AD的研究。此外,我们将讨论一些可能有效确定AD风险的病原体相关生物标志物。增加AD风险的感染是一种可通过治疗干预加以治疗的可改变风险因素。基于病原体的生物标志物因此可能是评估和降低整个人群AD风险的宝贵工具。